Amicus Repositions With A Focus On Combining Chaperones With ERTs

Biotech re-obtains all rights to migalastat from GSK, buys out ERT specialist Callidus and will raise $40 million through a private placement and a debt financing. Callidus co-founder, a former Genzyme scientist, will take over the Amicus’ scientific team, while the company slashes its overall headcount by 14%.